Get started
MODERNAMODERNAMODERNA

MODERNA

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

1MRNA trade ideas

$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9) Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble? CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍 (2/9) – PRICE PERFORMANCE 📊 • Current Trend: Up 9% after CEO’s $5M buy on Mar 5, 2025 💰 • Context: Biotech’s a rollercoaster—posts on X show optimism 📈 • Sector Vibe: Volatile, but insider faith lifts spirits 🌈 It’s a wild climb—buckle up! ⚡ (3/9) – MARKET POSITION 📈 • Market Cap: Around $12B (based on 384M shares, est.) 🏅 • Operations: mRNA pioneer, vaccines to cancer therapies ⏳ • Trend: CEO’s move signals undervaluation hope 🎯 Solid player in the biotech jungle! 🌋 (4/9) – KEY DEVELOPMENTS 🔑 • Insider Buying: CEO’s $5M grab on Mar 5, 2025 🔄 • Buzz: Posts on X tie surge to leadership confidence 🌐 • Reaction: Market cheers, up 9% in a blink 📣 Risin’ like dough in a warm oven! 🔥 (5/9) – RISKS IN FOCUS ⚠️ • Volatility: Biotech swings wild amid macro uncertainty 🔎 • Policy: Healthcare shifts could sting 📉 • Pipeline: New products unproven, per X chatter 🌬️ High stakes, high drama! 🎭 (6/9) – SWOT: STRENGTHS 💪 • Innovation: mRNA tech reshapes medicine 🏆 • Confidence: CEO’s $5M bet screams belief 📊 • Legacy: COVID vaccine king, still swinging ⚒️ A biotech beast with bite! 🐺 (7/9) – SWOT: WEAKNESSES & OPPORTUNITIES ⚖️ • Weaknesses: Volatility, macro jitters hit hard 📉 • Opportunities: New mRNA goodies, partnerships loom 📈 Can it brew more magic or fizzle out? 🧪 (8/9) – 📢 Stock up 9% after CEO’s $5M buy—your call? 🗳️ # • Bullish: $50+ soon, biotech boom 🚀 • Neutral: Holding steady, risks weigh ⚖️ • Bearish: $25 looms, bubble bursts 🐻# Drop your vote below! 👇 (9/9) – FINAL TAKEAWAY 🎯 Moderna’s 9% pop on insider buying hints at hidden gems 📈, but biotech’s a stormy sea 🌊. Dips are our playground—DCA heaven 💸. Snag ‘em cheap, ride the wave! Winner or wild card?
NASDAQ:MRNALong
by DCAChampion
6
MRNA'Ticker: MRNA Direction: Up Prognosis: Buy Calls (Author bought $40 and $41 calls expiring this week, considering rolling to later dates) Reasoning: New Covid-like virus discovered, rising avian flu concerns, large institutional buying, bullish technical indicators (RSI divergence, MACD turning up), high call option volume and open interest. Author acknowledges that a drop below $30 could invalidate the thesis. Disclaimer: This is not financial advice. MRNA is volatile; know your risk tolerance. Bonus: Author also mentions potential plays on HD puts, LOW puts, and CLF calls.'
NASDAQ:MRNA
by JustAHunch
Strength on MRNADespite negative news, Moderna, Inc. stock is in a good position to rally. Its price has been falling since August 2021, but relatively big buys have begun to emerge since August 2024. It has to be noted that on every bar with buying, volume is increasing, which is usually a sign of accumulation on a down move. If the price breaks the $40.83 level (the high of the bar with the largest volume), then tests it on low volume later, and supply does not re-emerge in the $49.94 - $56.70 zone, this would signal the end of accumulation. In such a case, we could expect the move towards $102.90 - $118.10, and if shares would not be sold off there, it might go even higher to $156.94 - $163.19. At the same time, if accumulation has not been finished yet, we may still see another leg down for more buying.
NASDAQ:MRNALong
by VSA_Home
6
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment among investors. Weighing the Challenges and Opportunities On Friday, Moderna disclosed a Q4 2024 revenue of $966 million, marking a sharp 65% year-over-year decline. The loss per share stood at $2.91, exceeding the analyst projection of $2.73 per share. More concerning for investors was the company’s forecast for 2025 sales, estimated between $1.5 billion and $2.5 billion—significantly below the $3.26 billion consensus estimate. CEO Stéphane Bancel reaffirmed Moderna’s focus on cutting costs and streamlining its research and development (R&D) efforts. The company plans to reduce R&D expenses by up to $1.1 billion by 2027, primarily by halting early-stage projects and prioritizing late-stage drug approvals. Moderna has already trimmed $1 billion in costs, positioning itself for leaner operations in the coming years. Technical Analysis: Key Levels to Watch From a technical perspective, NASDAQ:MRNA shares closed Friday’s session down 0.38%, showing hesitation despite the broader market’s strength. The stock is currently hovering near a critical support zone—the one-month low. Should this level fail to hold, a further decline towards the $25 region could be the next stop. On the upside, a breakout above the 38.2% Fibonacci retracement level could alter the trajectory for Moderna’s stock, potentially signaling a bullish reversal. However, with the Relative Strength Index (RSI) at 41.46, the stock remains in weak momentum territory, suggesting that bullish conviction is still lacking. Outlook: Can Moderna Reignite Investor Confidence? Moderna’s near-term outlook remains uncertain, as the company grapples with declining COVID vaccine sales, weaker-than-expected 2025 revenue projections, and an ongoing shift in its R&D strategy. However, its pipeline of combination vaccines and upcoming approvals may offer a longer-term upside if execution is successful. Technically, NASDAQ:MRNA needs to hold its key support zone and break above the 38.2% Fibonacci retracement to shift market sentiment positively. Until then, investors should watch for further signals of strength, particularly in trading volume and RSI movement, before confirming a potential bullish turnaround. In the coming months, all eyes will be on Moderna’s next earnings report and the market’s reaction to its cost-cutting measures and pipeline advancements. The stock’s ability to sustain recent gains—or break lower—will depend on whether the company can deliver on its strategic shifts and stabilize its revenue trajectory.
NASDAQ:MRNALong
by DEXWireNews
$MRNA to $90-115 | 100-150% upside in FY 2025- NASDAQ:MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco. - This company is beaten down to the ground and has low market cap as compared to other biopharma stocks. - 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth. - Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
NASDAQ:MRNALong
by bigbull037
$MRNA has 50-100% upside from $43 in FY 2025- NASDAQ:MRNA had one of the worst year in 2024. However, cash position is underestimated and the market cap has gotten very low for a company which has proven it's excellence in manufacturing drug and research. - NASDAQ:MRNA is working on cancer prevention vaccines which might get approvals in 2026 which will be a huge propeller for the stock long term. - In the short term 2025, Bird flue and HMPV in China should push the stock higher to it's fair value around $65-90 range before end of the year. - Wall street & Media pundits are saying nothing to worry about. But it's better to front run on these type of situations if you want to score big gains.
NASDAQ:MRNALong
by bigbull037
6
Moderna (MRNA) Down 92% from All-Time High – What's Next?Overview: Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower? Key Insights: Support Levels: Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area. Catalysts to Watch: Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
NASDAQ:MRNA
by SpokoStocks
The Share Price of Moderna (MRNA) Surged Over 10% in a DayThe Share Price of Moderna (MRNA) Surged Over 10% in a Day As shown by the chart of pharmaceutical company Moderna (MRNA): → 2024 was an extremely difficult year, with the price falling by approximately 60%; → however, in early 2025, we can see signs of renewed strength. During yesterday’s session, Moderna’s (MRNA) share price rose by more than 10%, following news of the first death in the US from H5N1 bird flu. According to Barron’s, Moderna is one of the few pharmaceutical companies currently developing a vaccine for H5N1 bird flu, which is spreading rapidly across North America. This brings back memories of 2020, when MRNA’s share price surged with a significant bullish gap on news of the COVID-19 vaccine trials. Interestingly, the 2024 low is near the lower boundary of the 2020 gap, around the $37 level. From a technical analysis perspective, this “gap closure” could be viewed as a bullish sign, supported by yesterday’s price action. Additionally: → there has been a breakout above the descending trend channel that dominated the end of 2024; → it is possible that price movements may form a new ascending channel (shown in blue); → further growth may be hindered by the psychological resistance level of $50. According to TipRanks, analysts remain cautious about Moderna’s prospects: → only 4 out of 19 analysts recommend buying MRNA shares; → the average 12-month price target for MRNA is $62. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
NASDAQ:MRNA
by FXOpen
2
Halftime Update: MRNA - Moderna AnalysisMRNA is currently retesting a pivotal level of resistance that we believe could provide a greater push back to those higher $58.55 Price Levels as long as it can keep this momentum that it has, seeing a very large volume spike in this morning. If not, we would expect some consolidation back to $45.42 levels before pushing higher. Stock jumped this morning after reporting a potential vaccine to combat the recent H5N1 Bird Flu. This comes after the first human death due to the Bird Flu in Louisiana, although the patient did have pre-existing medical conditions that contributed to the death, not to stir any feathers. Don't really have a price projection or entry specifically for this as we're watching. This could pull back to those EMAs before gaining True Momentum Northward. Connect with us by visiting the website below in our signature to get even more at @MyMIWallet #MyMIWallet
NASDAQ:MRNALong
by MyMIWallet
Moderna (MRNA): mRNA Leader Trading at a 90% Discount1️⃣ mRNA Technology Leadership: Moderna is revolutionizing vaccine development with its cutting-edge mRNA platform, positioning itself as a leader in the future of healthcare innovation. 2️⃣ Analyst Targets: With 28 ratings averaging $71.40 and highs of $85, Moderna offers over 60% upside from current levels. 3️⃣ Expanding Pipeline: Moderna’s broadening pipeline includes a variety of treatments, giving it multiple high-growth opportunities in the healthcare sector. 4️⃣ Technical Momentum: Moderna is holding key support at $43.85, with bullish signals of upward movement. The stock is primed for a breakout, supported by increasing volume and positive market sentiment. 📈 Trade Setup: 🎯 Take Profit 1: $50 (+14% potential gain) 🎯 Take Profit 2: $60 (+37% potential gain) 🏆 Take Profit 3: $70 (+59% potential gain) 📉 Stop Loss: $35 ⚠️ (For those with a conservative risk profile, but not necessary for long-term holders like myself)
NASDAQ:MRNALong
by ValchevFinance
1